Bitcoin's price fell from about $85.7K to $82.5K, triggering over $2.4 billion in liquidations mostly on long positions. The decline coincided with rising US Treasury yields above 5.3%, higher oil prices, and significant outflows from Bitcoin ETFs, reflecting broader market stress. Despite the sell-off, total open interest in futures remained steady near $150 billion, indicating no full market capitulation. Traders are now watching key support levels around $82,500 for signs of recovery or further decline.
Bitcoin's recent price movement is noted here alongside Pluang's cryptocurrency market data for context. For readers following crypto markets, as of Oct 10, 2026 13:51 WIB, 32 of 50 major cryptocurrencies on Pluang rose while 17 fell. Among notable movers, ADA (Cardano) increased 5.11% to Rp4.502 with a typical hold time of 126 days and 78% buy order activity; FIL (Filecoin) rose 4.94% to Rp20.657 with a 99-day hold time and balanced sell/buy orders; CAKE (PancakeSwap) gained 4.81% to Rp40.391 with a 75-day hold time and 74% buy orders.
At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...
Bitcoin's price remains stable around $82,500 even as reports emerge about a theft involving Ledger, a popular crypto hardware wallet provider. This resilience suggests investor confidence in Bitcoin's value despite security concerns in the crypto sp...
Bitcoin briefly fell below $81,000 before recovering to around $82,500, triggered by $1.09 billion in forced liquidations of leveraged crypto positions, mostly from traders betting on price increases. This sell-off added pressure on digital assets, c...
Bitcoin stabilized around $82,500 following a sharp drop to $80,350 caused by a security exploit involving Ledger hardware wallets. The incident led to over $1 billion in crypto liquidations within 24 hours, shaking investor confidence, especially am...
Entrada Therapeutics is rated Buy with a fair value of $8.50, implying about 52% upside from the current $5.61 price. The company’s Duchenne muscular dystrophy drug ENTR-601-44 showed a disappointing initial increase in dystrophin, but this is attrib...
